LIXTE Biotechnology Holdings to Present at Spartan Capital Investor Conference 2025 on November 3

LIXTE Biotechnology Holdings, a clinical-stage pharmaceutical company, will present at the Spartan Capital Investor Conference 2025. CEO Geordan Pursglove will present on November 3 at 4 p.m. ET, with one-on-one meetings available. The conference will be held at the Marriott Marquis Hotel in New York. LIXTE focuses on new targets for cancer drug development and is developing and commercializing cancer therapies. Its lead compound, LB-100, is a first-in-class inhibitor of protein phosphatase 2A (PP2A).